entertainment -WSS

entertainment

author：comprehensive 2025-10-01 10:36:06 - browse：5

A sign of pharmaceutical company Bayer in front of a blossomed tree — coverage from STAT — INA FASSBENDER/AFP via Getty Images

More hopeful news on the menopause front: Bayer announced on Monday encouraging results in two Phase 3 trials for its non-hormonal drug candidate, elinzanetant, meant to treat hot flashes. The results follow the recent market launch of Veozah, Astellas Pharma’s groundbreaking non-hormonal treatment for hot flashes, which was approved by the U.S. Food and Drug Administration last spring and received approval in the U.K., under the name Veozah, in December.

Elinzanetant is a neurokinin-1 and 3 receptor antagonist, and works by calming down the estrogen receptors in the brain that become hyperactive around menopause, causing hot flashes. The drug, a pill administered once a day, was shown to reduce both the frequency and intensity of hot flashes, and also met the secondary endpoints for improving sleep and quality of life, according to JoAnn Pinkerton, professor of obstetrics and gynecology and director of the Midlife Health at UVA Health, who is a clinical investigator for Bayer’s drug candidate.

Pinkerton said she was excited to see the broader quality of life improvements through elinzanetant: “Women have more than just hot flashes — it’s actually more about hot flushes, sweats, fatigue, lack of sleep and some of the mood changes that go on during [menopause].”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Sports medicine is finally prioritizing gender equality
Next article： 'The View' co

Wikipedia

WSS

Hey, doctors: Don't be no

Study: Misdiagnosis causes 800,000 deaths, serious disabilities a year in U.S.

It's time to take a new tack for treating Alzheimer's

How Brent Saunders' Allergan experiment failed

Dispute over threat of extinction posed by artificial intelligence looms over surging industry

Readout Newsletter: CG Oncology IPO, Eli Lilly, Tesla, Merck

hotspot

entertainment

knowledge

At least 13 dead in Texas as scorching temps continue

Pfizer's RSV vaccine recommended for approval in Europe

As demand for Covid shots wanes, Moderna seeks its next success

Merck CEO won’t testify in Senate, citing no expertise in drug prices

23andMe had bad news about my health. I wish a person had delivered it

Why Marc Tessier

After affirmative action ruling, medical educators look to 'holistic review'

Medicare Advantage insurers face 0.2% cut to 2025 payments

United colonoscopy coverage change 'may cost lives,' doctors say

Merck, Johnson & Johnson CEOs will testify on high drug prices

focus

It's time to take a new tack for treating Alzheimer's

Medicare drug price negotiation legal challenge met with skepticism

Boston competes with Raleigh

Mega Millions jackpot grows to $720 million ahead of Friday's drawing

Why Marc Tessier

Readout Newsletter: Vertex, Pfizer, Kura, and other biotech news

hotspot

focus

Wikipedia

leisure time